Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)

Tucker W. LeBien, Janet M. Anderson, Daniel A. Vallera, Fatih M. Uckun

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Studies were undertaken to examine the efficacy of combining monoclonal antibodies BA-1, BA-2, BA-3 + complement with a stabilized derivative of cyclophosphamide (mafosfamid) for elimination of leukemic cell line clonogenic cells. In a series of experiments conducted with leukemic cell lines a combination of two cycles of treatment with BA-1, 2, 3 + complement combined with 25 μg/ml-1 mafosfamid was superior to either modality alone in killing clonogenic leukemic cells. Identical treatment of normal bone marrow had no effect on the monopotent stem cells CFU-E and CFU-GM, or the pluripotent stem cell CFU-MIX, but some inhibition of the monopotent stem cell CFU-MK did occur. These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalLeukemia research
Volume10
Issue number2
DOIs
StatePublished - 1986

Keywords

  • Autologous bone marrow transplantation
  • mafosfamid
  • monoclonal antibody + complement

Fingerprint Dive into the research topics of 'Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)'. Together they form a unique fingerprint.

  • Cite this